Overview
- The Kumamoto University team, which published its preclinical results Tuesday in Molecular Pharmaceutics, showed oral doses brought diabetic mice’s blood sugar back to normal.
- The method uses a cyclic “DNP” peptide that crosses the small intestine to carry insulin into the blood, avoiding breakdown by digestive enzymes and the gut’s poor uptake of large proteins.
- The researchers proved two routes worked in mice: a mixing method pairing a modified D-DNP-V peptide with zinc-stabilized insulin hexamers, and a conjugation method that clicks the peptide directly onto insulin.
- Both approaches cut the dose burden by achieving about 33–41% pharmacological bioavailability versus standard subcutaneous shots, a sharp improvement over past oral attempts that needed far higher amounts.
- The group plans larger-animal tests and studies in human-like intestinal systems before any trials in people, a step that could ease daily injections and may open a path for long-acting insulins and other biologic drugs.